The Catalyst



Last year, the National Pharmaceutical Council (NPC) released a survey of health care stakeholders on comparative effectiveness research (CER).


This week we featured two posts from PhRMA's President and CEO John Castellani, both of which looked at the global challenges facing the pharmaceutical industry.


The National Institute for Allergy and Infectious Diseases yesterday put out a great new video about the prescription drug discovery process which emphasized the importance of medical innovation partnerships.


I've written before about our partnership with and their incredible work last year on The Prescription Drug Abuse Project made some real headlines.


Reading Matthew Yglesias' post in Slate on Thursday about why Medicare Part D costs less than predicted, I found his argument a bit odd.

03.14.13 | By Christian Clymer

Today, we are happy to feature a guest post from Alan Moses, Senior Vice President and Global Chief Medical Officer at Novo Nordisk


During many conversations I have had with friends, family members and new acquaintances, I've found that many people don't quite understand the difference between a biologic and a traditional chemical medicine (oftentimes found in a pill form). But who can blame them?

03.13.13 | By John Castellani

Today's House Ways and Means Trade Subcommittee hearing on U.S. - India trade relations could not be more timely.

03.12.13 | By John Castellani

The growing threat posed by counterfeit medicines warrants cross-border and public-private collaboration of the highest magnitude.

03.11.13 | By Preet Bilinski

Biologics are at the cutting-edge of research and changing our ideas about drug discovery and development.


There seems to be an increased curiosity these days about interactions between biopharmaceutical research companies and healthcare professionals.

03.07.13 | By Preet Bilinski

Patients should be able rely on and trust their prescriptions. After leaving the doctor's office or pharmacy, patients should not have to second-guess whether their prescriptions are safe.


I explored a new study from the National Bureau of Economic Research (NBER) today and was encouraged by its balanced views on direct to consumer advertising (DTC), including recognition that DTC advertising helps


Last week's op-ed in the Washington Post ("Making cancer drugs less expensive") highlighted some important issues r

03.06.13 | By Stephanie Fischer

As we prepare to release the next Medicines in Development report which will highlight biologics, we invited the Life Sciences Found


A commentary posted today on Forbes nicely captures the vital importance of well-funded basic biomedical r


03.04.13 | By Jay Taylor


03.04.13 | By Mark Grayson